SCHEMBL5330840

SCHEMBL5330840

CCN(CC)C(=O)/C(C#N)=C/c1cc(OC(=O)OCc2ccccc2)c(O)c([N+](=O)[O-])c1

nearest known ligand 0.62

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
▸ FTO Q9C0B1 6/20 0.62
▸ MEN1 O00255 4/20 0.62
▸ KMT2A Q03164 4/20 0.62
▸ COMT P21964 2/20 0.62
▸ ABCC3 O15438 1/20 0.62
▸ ABCC4 O15439 1/20 0.62
▸ ABCB11 O95342 1/20 0.62
▸ LMNA P02545 1/20 0.62
▸ CYP2C9 P11712 1/20 0.62
▸ GPR35 Q9HC97 1/20 0.62
▸ EGFR P00533 2/20 0.47
▸ MAPT P10636 3/20 0.44
▸ KDM4E B2RXH2 2/20 0.44
▸ ALDH1A1 P00352 2/20 0.44
▸ NPC1 O15118 1/20 0.44
▸ POLB P06746 1/20 0.41
▸ HPGD P15428 1/20 0.41
▸ MCL1 Q07820 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5330846 1.00 FTO (0.62) FTOMEN1KMT2ACOMTABCC3
SCHEMBL5326812 0.92 FTO (0.61) FTOMEN1KMT2ACOMTABCC3
SCHEMBL5326818 0.92 FTO (0.61) FTOMEN1KMT2ACOMTABCC3
SCHEMBL4940766 0.92 MEN1 (0.60) FTOMEN1KMT2ACOMTABCC3
SCHEMBL4940753 0.92 MEN1 (0.60) FTOMEN1KMT2ACOMTABCC3
SCHEMBL4939502 0.92 KMT2A (0.55) FTOMEN1KMT2ACOMTABCC3
SCHEMBL4939512 0.92 KMT2A (0.55) FTOMEN1KMT2ACOMTABCC3
SCHEMBL5324586 0.91 KMT2A (0.59) FTOMEN1KMT2ACOMTABCC3
SCHEMBL5324591 0.91 KMT2A (0.59) FTOMEN1KMT2ACOMTABCC3
SCHEMBL4937410 0.90 FTO (0.54) FTOMEN1KMT2ACOMTABCC3

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20080103191-A1 ENTACAPONE-DERIVATIVES SCHWARZ PHARMA AG (DE) 2008-05-01 — — US disclosed
US-20080103191-A1 ENTACAPONE-DERIVATIVES SCHWARZ PHARMA AG (DE) 2008-05-01 — — US disclosed
WO-2007144169-A2 ENTACAPONE-DERIVATIVES SCHWARZ PHARMA AG (DE) 2007-12-21 — — WO disclosed
WO-2007144169-A2 ENTACAPONE-DERIVATIVES SCHWARZ PHARMA AG (DE) 2007-12-21 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080103191-A1 ENTACAPONE-DERIVATIVES ENTPD5, ENTPD3, ENTPD1 FTO 2243/4885MEN1 1023/4885KMT2A 4545/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback